RNS Number: 0408 T AstraZeneca PLC 12 November 2019 12 November 2019 07:00 GMT. Anifrolumab demonstrated superiority across multiple efficacy endpoints. in patients with systemic lupus erythematosus in Phase III TULIP 2 trial.
RNS Number: 8848 S AstraZeneca PLC 11 November 2019 11 November 2019 07:00 GMT. Roxadustat Phase III programme pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anaemia from chronic kidney disease. The results were presented in an oral late-breaking abstract session at the American Society of Nephrology...
AstraZeneca and FibroGen Inc. today presented pooled efficacy and cardiovascular safety analyses from the pivotal Phase III program assessing roxadustat for the treatment of patients with anemia from chronic kidney disease. The results were presented in an oral late-breaking abstract session at the American Society of Nephrology Kidney Week 2019 in...
AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA ® for the treatment of heart failure. The data showed that FARXIGA on top of standard of care reduced the incidence of the primary composite endpoint of cardiovascular death or worsening of HF in patients with HF with reduced...
RNS Number: 7220 S AstraZeneca PLC 08 November 2019 8 November 2019 07:00 GMT. Roxadustat significantly increased haemoglobin levels for chronic kidney disease patients with anaemia in Phase III OLYMPUS and ROCKIES trials. The results were presented today during two oral sessions at the American Society of Nephrology Kidney Week 2019 in Washington, D.C., US..
AstraZeneca today presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased hemoglobin levels in both non-dialysis-dependent and dialysis-dependent patients with anemia from chronic kidney disease, respectively. The results were presented today during two oral sessions at the...
AstraZeneca will present the first data from the Phase III ELEVATE-TN trial assessing CALQUENCE ®, a next-generation selective Bruton’ s tyrosine kinase inhibitor, in patients with previously untreated chronic lymphocytic leukemia, as well as data from novel-combination trials across multiple blood cancers at the 2019 American Society of Hematology...
RNS Number: 5205 S AstraZeneca PLC 06 November 2019 6 November 2019 14:00 GMT. Calquence data to show improved progression-free survival in Phase III front-line chronic lymphocytic leukaemia trial at ASH 2019 Annual Meeting. AstraZeneca will present the first data from the Phase III ELEVATE-TN trial assessing Calquence, a next-generation selective...
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6. 1. As at 31 October 2019 the issued share capital of AstraZeneca PLC with voting rights is 1,311,904,600 ordinary shares of US $0.25. The above figure for the total number of voting rights may be used by shareholders as the...
AstraZeneca will present pooled efficacy and cardiovascular safety analyses from the Phase III clinical program of roxadustat for the treatment of anemia from chronic kidney disease in non dialysis-dependent or dialysis-dependent patients. The data are among an unprecedented 41 AstraZeneca abstracts including three late-breakers, accepted for...
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia. AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection...
AstraZeneca today announced positive progression-free survival results for IMFINZI and tremelimumab, an anti-CTLA-4 antibody, when added to chemotherapy, from the Phase III POSEIDON trial in previously-untreated Stage IV non-small cell lung cancer. The trial met a primary endpoint by showing a statistically significant and clinically meaningful...
RNS Number: 3760 R AstraZeneca PLC 28 October 2019 This announcement contains inside information. 28 October 2019 15:15 GMT. Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st- line treatment of Stage IV non-small cell lung cancer.
Pharmaceuticals group AstraZeneca saw product sales increase by 16% to $6.13bn in the third quarter of this year, its fifth consecutive quarter of growth. The group achieved new medicines sales growth of 62%, with its three therapy areas and all its sales regions producing “encouraging” performances. Sales were up by 46% in oncology,15% in respiratory therapies and 8% in cardiovascular, renal and metabolism treatments. Revenues were also up by 35% in China, 31% in Japan, 25% in emerging markets, 17% in the US and 1% in Europe. Overall, in the first nine months of this year, sales were up by 13% to $17.3bn. Chief executive Pascal Soriot says Astrazeneca is “growing at pace” and has upgraded its sales guidance for the second consecutive quarter.
AstraZeneca Plc (AZN.L) Announced, in its quarterly results for the quarter ended 30 September 2019, that revenues rose to $6,406.0 million from $5,340.0 million recorded same period a year ago. Profit after tax narrowed to $280.0 million from $406.0 million. Additionally, the company, in its financial results for the nine months ended 30 September 2019, announced that revenues climbed to $17,720.0 million from $15,673.0 million recorded in the same period previous year. Profit after tax narrowed to $950.0 million from $1,041.0 million. The record date for the second interim dividend for 2019, payable on 30 March 2020, will be 28 February 2020. The ex-dividend date will be 27 February 2020. The record date for the first interim dividend for 2020, payable on 14 September 2020, will be 14 August 2020. The exdividend date will be 13 August 2020.
Year-to-date Product Sales growth of 13% to $17,315 m included third-quarter Product Sales of $6,132 m. -Sales growth by region in the quarter: total Emerging Markets sales grew by 25% to $2,123 m, with China sales growth of 35% to $1,283 m, ahead of longer-term trends. US sales increased by 17% to $2,025 m; Europe sales continued their return to growth, increasing by...
AstraZeneca today announced that the US Food and Drug Administration has approved FARXIGA to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Stephen Wiviott of Brigham and Women’ s Hospital and Harvard Medical School, Boston, and a Senior...
AstraZeneca Plc (AZN.L) Announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. The approval is based on results from the landmark DECLARE-TIMI 58 CV outcomes trial (CVOT), the largest sodiumglucose cotransporter 2 (SGLT2) inhibitor CVOT conducted to date to evaluate T2D patients with multiple CV risk factors or established CV disease.
RNS Number: 5063 Q AstraZeneca PLC 21 October 2019 21 October 2019 07:00 BST. Stephen Wiviott of Brigham and Women's Hospital and Harvard Medical School, Boston, US and a Senior Investigator with the TIMI study group and co-principal investigator of the trial, said: "DECLARE-TIMI 58 is a landmark trial, offering compelling evidence that dapagliflozin can reduce...
AstraZeneca and Daiichi Sankyo Company, Limited today announced that the US Food and Drug Administration has accepted for review the Biologics License Application for trastuzumab deruxtecan and granted Priority Review. The Prescription Drug User Fee Act date for trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate and potential new...
AstraZeneca Plc
AZN.L
AstraZeneca Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    1.27B

Company Profile

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Classification

Market Indices-

Locations

HQ
Cambridge Biomedical Campus
1 Francis Crick Avenue
Cambridge
CB2 0AA
Watchlist